IRLAB Therapeutics AB is a Sweden-based research and development company. It focuses on illnesses in the central nervous system and primarily on development of drugs to assist patients with Parkinsonâ€™s disease. The Company possesses a research platform Integrative Screening Process (ISP), which aims to discover and develop drug candidates for the treatment of brain diseases. The Company operates projects on both clinical phase and preclinical phases. The primary projects are IRL790 and IRL752, both on clinical phase. The IRL790 project is a psychomotor stabilizer for the treatment of levodopa (L-dopa) amino acid that dyskinesia induces in Parkinsonâ€™s Disease (PD-LIDs) and Parkinson Disease psychosis (PD-Psychosis). The IRL752 project aims at cortical enhancement for the treatment of Parkinson Disease Dementia (PD-D) and Behavioral and Psychological Symptoms of Dementia (BPSD).

Employees

Sector

Pharmaceuticals

Calendar

08-26 Earnings release - Q2 2026

More about the company

07-08	Irlab board member James Gamgort buys shares for just under SEK 0.3m	FW
07-01	IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors	CI

Market Cap	183M 18.84M 16.55M 15.45M 14.18M 26.54M 1.8B 27.2M 71.65M 893M 70.73M 69.19M 3.09B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	183M 18.84M 16.55M 15.45M 14.18M 26.54M 1.8B 27.2M 71.65M 893M 70.73M 69.19M 3.09B	EV / Sales 2026 *	1.8x	EV / Sales 2027 *	1.29x
Free-Float	81.63%	Yield 2026 *	-	Yield 2027 *	-

07-08	Irlab board member James Gamgort buys shares for just under SEK 0.3m	FW
07-01	IRLAB Therapeutics AB Approves Election of Janne Backman as Vice Chairperson of the Board of Directors	CI
06-30	IRLAB Therapeutics Rights Issue Raises About SEK 68 Mln	RE
06-30	Irlab Therapeutics Raises SEK76.5 Million from Oversubscribed Rights Offering	MT
06-30	Irlab rights issue oversubscribed	FW
06-16	IRLAB Therapeutics Presents Integrated Analysis of Mesdopetam Data at International Conference and Confirms Robust Efficacy Results in The Phase II Studies	CI
06-16	Irlab highlights positive data for mesdopetam	FW
06-08	Irlab shares trade ex-rights on Nasdaq Stockholm following rights issue	FW
06-06	IRLAB Therapeutics AB Announces Board Elections, Effective June 5, 2026	CI
06-05	Irlab rights issue now 91 percent secured	FW
05-06	IRLAB Q1 operating result swings to profit of SEK 10.7 mln	RE
05-06	Irlab reports growth in revenue and operating profit	FW
05-06	IRLAB Therapeutics AB Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

11-04	Redeye Lowers Fair Value for Irlab to 12 Kronor (from 17)	FW
13/05/24	Irlab rises almost double-digit - Redeye raises motivated value	FW
13/05/24	Redeye raises motivated value for Irlab to SEK 40 (35)	FW
12/02/24	Edison lowers motivated value for Irlab	FW
30/12/23	Bonesupport winner of the year and Viaplay loser of the year on Nasdaq Stockholm 2023	FW

07-10	IRLAB Therapeutics : rights issue is registered – conversion of BTA into shares	PU
06-30	Report from the Annual General Meeting 2026 of IRLAB Therapeutics AB	AQ
06-16	IRLAB Presents Integrated Analysis of Mesdopetam Data at International Conference - Confirms Robust Efficacy Results in the Phase II Studies	AQ
06-16	IRLAB presents integrated analysis of mesdopetam data at international conference – confirms robust efficacy results in the Phase II studies	AQ
06-05	IRLAB publishes information document in connection with the rights issue and announces that additional subscription undertakings have been received	AQ

IRLAB Therapeutics AB Stock Nasdaq Stockholm

Stocks

Pharmaceuticals

Valuation: IRLAB Therapeutics AB

Latest news : IRLAB Therapeutics AB

Last Transcript: IRLAB Therapeutics AB

Analysts' recommendations: IRLAB Therapeutics AB

Press Releases: IRLAB Therapeutics AB

News in other languages: IRLAB Therapeutics AB

Managers and Directors: IRLAB Therapeutics AB

Other Pharmaceuticals

Financials

Company Profile

End-of-day quote Nasdaq Stockholm Other stock markets
- ^SEK	-

Manager	Title	Age	Since
Clas Sonesson CTO	Chief Tech/Sci/R&D Officer	65	01/01/2016
Susanna Waters PRN	Corporate Officer/Principal	60	01/01/2013
Kristina Torfgård CEO	Chief Executive Officer	63	01/08/2024

Director	Title	Age	Since
Rein Piir BRD	Director/Board Member	68	01/01/2016
Gunnar Olof Olsson CHM	Chairman	73	07/05/2020
Carola Elisabet Lemne CHM	Chairman	68	20/02/2023

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ELI LILLY AND COMPANY	-0.40%	+4.89%	+59.89%	+168.38%	1,089B
JOHNSON & JOHNSON	-0.39%	+4.35%	+58.68%	+59.23%	643B
ABBVIE INC.	+0.79%	+5.22%	+39.38%	+78.18%	465B
ROCHE HOLDING AG	-1.69%	+8.81%	+39.38%	+33.67%	359B
NOVARTIS AG	-0.51%	+3.51%	+36.97%	+42.46%	303B
ASTRAZENECA PLC	+1.50%	+3.40%	+17.71%	+17.41%	267B
NOVO NORDISK A/S	+0.79%	+5.81%	-2.55%	-38.10%	226B
AMGEN INC.	-1.06%	+6.40%	+28.30%	+66.33%	212B
GILEAD SCIENCES, INC.	-0.25%	+3.03%	+17.56%	+76.37%	167B
Average	-0.06%	+5.07%	+32.81%	+55.99%	414.57B
Weighted average by Cap.	-0.07%	+5.14%	+42.80%	+81.89%

	2026 *	2027 *
Net sales	102M 10.49M 9.22M 8.6M 7.89M 14.78M 1B 15.14M 39.89M 497M 39.37M 38.52M 1.72B	142M 14.58M 12.81M 11.96M 10.97M 20.54M 1.4B 21.05M 55.45M 691M 54.74M 53.55M 2.39B
Net income	-32.6M -3.35M -2.95M -2.75M -2.52M -4.72M -321M -4.84M -12.75M -159M -12.58M -12.31M -549M	33.3M 3.42M 3.01M 2.81M 2.58M 4.82M 328M 4.94M 13.02M 162M 12.85M 12.58M 561M
Net Debt	-	-